CA2316447A1 - Rantes mutants and therapeutic applications thereof - Google Patents
Rantes mutants and therapeutic applications thereof Download PDFInfo
- Publication number
- CA2316447A1 CA2316447A1 CA002316447A CA2316447A CA2316447A1 CA 2316447 A1 CA2316447 A1 CA 2316447A1 CA 002316447 A CA002316447 A CA 002316447A CA 2316447 A CA2316447 A CA 2316447A CA 2316447 A1 CA2316447 A1 CA 2316447A1
- Authority
- CA
- Canada
- Prior art keywords
- rantes
- therapeutic applications
- rantes mutants
- mutants
- wild
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000001327 Chemokine CCL5 Human genes 0.000 title abstract 4
- 108010055166 Chemokine CCL5 Proteins 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000036436 anti-hiv Effects 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000000043 antiallergic agent Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
RANTES mutants characterised by the substitution or addition of amino acids at the N-terminal of RANTES wild-type sequence and in the N-loop and/or 40's loop regions of RANTES wild-type sequence, and their use as anti-HIV, anti-allergic or anti-inflammatory agents.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI97A002865 | 1997-12-23 | ||
| ITMI972865 IT1297015B1 (en) | 1997-12-23 | 1997-12-23 | RANTES mutants, useful for inhibiting HIV |
| ITMI98A001866 | 1998-08-07 | ||
| IT98MI001866 IT1302012B1 (en) | 1998-08-07 | 1998-08-07 | RANTES mutants, useful for inhibiting HIV |
| PCT/EP1998/008354 WO1999033989A2 (en) | 1997-12-23 | 1998-12-21 | Rantes mutants and therapeutic applications thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2316447A1 true CA2316447A1 (en) | 1999-07-08 |
| CA2316447C CA2316447C (en) | 2009-07-28 |
Family
ID=26331556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002316447A Expired - Fee Related CA2316447C (en) | 1997-12-23 | 1998-12-21 | Rantes mutants and therapeutic applications thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6608177B1 (en) |
| EP (2) | EP1431391B1 (en) |
| JP (1) | JP4323094B2 (en) |
| AT (2) | ATE308616T1 (en) |
| AU (1) | AU2415599A (en) |
| CA (1) | CA2316447C (en) |
| DE (2) | DE69832197T2 (en) |
| DK (2) | DK1040191T3 (en) |
| ES (2) | ES2247738T3 (en) |
| WO (1) | WO1999033989A2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6743594B1 (en) | 1995-06-06 | 2004-06-01 | Human Genome Sciences, Inc. | Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5) |
| US6025154A (en) | 1995-06-06 | 2000-02-15 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor HDGNR10 |
| UA77950C2 (en) * | 2000-10-04 | 2007-02-15 | Applied Research Systems | Use of mutants of cc chemokines for treatment of multiple sclerosis |
| US7175988B2 (en) | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
| AU2002358144B2 (en) | 2001-12-17 | 2008-10-02 | Laboratoires Serono Sa | Chemokine mutants acting as chemokine antagonists |
| US7393934B2 (en) | 2001-12-21 | 2008-07-01 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor (CCR5) HDGNR10 |
| JP2005529099A (en) * | 2002-04-04 | 2005-09-29 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | Chemokine mutants with improved oral bioavailability |
| WO2005105841A2 (en) | 2004-03-12 | 2005-11-10 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor (ccr5) hdgnr10 |
| AU2007323900B2 (en) * | 2006-11-13 | 2013-05-09 | Eli Lilly And Company | Therapeutic targeting of escort proteins |
| DK2185719T3 (en) * | 2007-08-02 | 2014-02-17 | Novimmune Sa | ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| CN112469430B (en) | 2018-05-28 | 2024-12-24 | 日内瓦大学 | Ways to suppress inflammation in the brain |
| WO2025172252A1 (en) * | 2024-02-15 | 2025-08-21 | Novo Nordisk A/S | Protracted ccr5 antagonists and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9703889A (en) * | 1994-12-08 | 1997-08-30 | Glaxo Group Ltd | Rantes peptide and fragments and compositions comprising it for treatment of inflammation. |
| FR2748938B1 (en) * | 1996-05-22 | 1998-07-31 | Pasteur Institut | USE OF ANTAGONIST MOLECULES OF CHEMOKINES FOR THEIR ANTIVIRAL ACTIVITY IN PARTICULAR AGAINST HIV-TYPE RETROVIRUSES |
| AU4561497A (en) * | 1996-09-25 | 1998-04-17 | British Biotech Pharmaceuticals Limited | Human rantes mutants incapable of aggregate formation |
-
1998
- 1998-12-21 AT AT98966650T patent/ATE308616T1/en active
- 1998-12-21 DE DE69832197T patent/DE69832197T2/en not_active Expired - Lifetime
- 1998-12-21 EP EP03027936A patent/EP1431391B1/en not_active Expired - Lifetime
- 1998-12-21 DK DK98966650T patent/DK1040191T3/en active
- 1998-12-21 CA CA002316447A patent/CA2316447C/en not_active Expired - Fee Related
- 1998-12-21 DK DK03027936T patent/DK1431391T3/en active
- 1998-12-21 ES ES98966650T patent/ES2247738T3/en not_active Expired - Lifetime
- 1998-12-21 WO PCT/EP1998/008354 patent/WO1999033989A2/en active IP Right Grant
- 1998-12-21 AU AU24155/99A patent/AU2415599A/en not_active Abandoned
- 1998-12-21 EP EP98966650A patent/EP1040191B1/en not_active Expired - Lifetime
- 1998-12-21 ES ES03027936T patent/ES2247475T3/en not_active Expired - Lifetime
- 1998-12-21 AT AT03027936T patent/ATE308617T1/en active
- 1998-12-21 DE DE69832216T patent/DE69832216T2/en not_active Expired - Lifetime
- 1998-12-21 JP JP2000526645A patent/JP4323094B2/en not_active Expired - Fee Related
-
1999
- 1999-07-08 US US09/581,070 patent/US6608177B1/en not_active Expired - Fee Related
-
2003
- 2003-03-28 US US10/400,487 patent/US7164000B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6608177B1 (en) | 2003-08-19 |
| ATE308616T1 (en) | 2005-11-15 |
| DE69832216T2 (en) | 2006-05-24 |
| WO1999033989A3 (en) | 1999-08-26 |
| US20030216549A1 (en) | 2003-11-20 |
| ATE308617T1 (en) | 2005-11-15 |
| DE69832197T2 (en) | 2006-05-24 |
| EP1431391A3 (en) | 2004-10-06 |
| EP1040191A2 (en) | 2000-10-04 |
| DK1431391T3 (en) | 2005-12-19 |
| US7164000B2 (en) | 2007-01-16 |
| EP1431391A2 (en) | 2004-06-23 |
| JP2002507388A (en) | 2002-03-12 |
| CA2316447C (en) | 2009-07-28 |
| WO1999033989A2 (en) | 1999-07-08 |
| ES2247738T3 (en) | 2006-03-01 |
| AU2415599A (en) | 1999-07-19 |
| EP1040191B1 (en) | 2005-11-02 |
| ES2247475T3 (en) | 2006-03-01 |
| JP4323094B2 (en) | 2009-09-02 |
| DE69832197D1 (en) | 2005-12-08 |
| DE69832216D1 (en) | 2005-12-08 |
| EP1431391B1 (en) | 2005-11-02 |
| DK1040191T3 (en) | 2005-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU4403689A (en) | Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids | |
| PL308122A1 (en) | Viral vectors and their application in genic therapy | |
| WO1998055508A3 (en) | HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS | |
| WO1995007992A3 (en) | Cloned glutamic acid decarboxylase | |
| CA2045869A1 (en) | Fusion proteins with immunoglobulin portions, the preparation and use thereof | |
| CA2223579A1 (en) | Novel recombinant temperature sensitive mutants of influenza | |
| WO1995013297A3 (en) | Improved immunogenic compositions against human gastrin 17 | |
| CA2316447A1 (en) | Rantes mutants and therapeutic applications thereof | |
| BG102362A (en) | New derivatives of amino acids, their preparation and application | |
| CA2058019A1 (en) | Use of pairs of peptides with extremely high specific affinity for one another in the area of in vitro diagnosis | |
| CA2120153A1 (en) | Recombinant immunotoxins | |
| EP0810285A3 (en) | Mutants of human Interleukin-3 | |
| DE59410132D1 (en) | HUMANESCIRCULAR CYTOKIN CC-1 | |
| AU2157888A (en) | Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids | |
| AU5591296A (en) | N-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl)benzamide derivatives, their preparation and their application in therapeutics | |
| AU4985596A (en) | Novel aroylaniline derivatives, compositions and uses thereof in the treatment of viral infections | |
| WO2000027880A3 (en) | Rantes-derived peptides with anti-hiv activity | |
| WO1998031712A3 (en) | Chitosan-conjugates with acidic chelate-complex forming agents | |
| CA2163805A1 (en) | Novel activating factor of leukocytes | |
| CA2118498A1 (en) | A novel anti-neoplastic cytokine | |
| CA2078000A1 (en) | Neutrophil stimulating peptides | |
| IT1244880B (en) | FORMULATIONS OF LYOPHILIZED AMINO ACIDS CONTAINING GLUTAMINE, THEIR PREPARATION AND USE IN THE PARENTERAL FEEDING | |
| Dozeman | The Life of Moses: The Yahwist as Historian in Exodus-Numbers | |
| CA2247998A1 (en) | Fragments of cr1 and their use | |
| HK2794A (en) | 8a-acylaminoergoline, its preparation and pharmaceutical compositions containing it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20131223 |